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ABSTRACT 
Lung Carcinogenesis Modeling: Resampling and Simulation Approach to Model Fitting, 
Validation, and Prediction 
by 
Millennia Foy 
Because of serious health implications, lung cancer is the leading cancer killer for 
both men and women. It is well known that smoking is the major risk factor for lung 
cancer. I propose to use a two-stage clonal expansion (TSCE) model to evaluate the 
effects of smoking on initiation and promotion of lung carcinogenesis. 
The TSCE model is traditionally fit to prospective cohort data. A new method has 
been developed that allows reconstruction of cohort data from the combination of risk 
factor data from a case-control study, and tabled incidence/mortality rate data. A 
simulation study of the method shows that it is accurate in estimating the parameters of 
the TSCE model. 
The method is then applied to fit a TSCE model based on smoking history. The 
fitted model is then validated in two ways. First the model is used to predict lung cancer 
deaths in the non-asbestos exposed control arm of the CARET study, where the model 
predicts 366.8 lung cancer deaths while there were 364 observed. Second, the model is 
used to simulate LC mortality in the US population and reasonably reproduced observed 
US mortality rates. 
iii 
The model is also applied to a study of CT screening for lung cancer. The study is 
a single arm CT screening study lacking a control arm for comparison. The model is used 
to simulate LC mortality in the absence of screening to serve as a surrogate control arm 
for comparison. Based on the model there is a statistically significant mortality reduction 
of 36% due to CT screening. 
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Chapter 1 
Background and Significance 
1.1 Introduction 
Lung cancer is the second leading cancer in terms of incidence for both men and 
women, second to prostate cancer for men and breast cancer for women. However, 
because of its serious health implications, lung cancer is the leading cancer killer for both 
men and women worldwide (Coleman et al 1993, NIH 2007). Once a patient is 
diagnosed, the prognosis is so poor that incidence data are often assumed to be equivalent 
to mortality data. Less than half of newly diagnosed cases live 1 more year. The 1-year 
survival rate increased from 37% in 1975 to 42% in 2000 while the 5-year survival rate 
for newly diagnosed cases is only 15% (Cancer Facts and Figures (CFF) 2009). The 
modest increase in 1-year survival could be due to advances in treatment such as surgical 
techniques, or the implementation of screening in some individuals. Although, screening 
for lung cancer is not yet recommended, some doctors are using chest x-ray or CT to 
screen for lung conditions in their patients. Lung cancer is a serious public health issue 
that needs to be studied in order to prevent lung cancer in those who do not have it, and 
improve survival in those who have been diagnosed 
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The goal of this project is to use carcinogenesis modeling, specifically the two-
stage clonal expansion (TSCE) model in conjunction with maximum likelihood methods 
to estimate the effects of different risk factors on the development of lung cancer. Since 
the TSCE model is incidence based, it is normally fit to prospective cohort data. For this 
study, cohort data is unavailable but case-control data on risk factor exposure and tabled 
age-specific mortality rates are available. This prompted the development of a new 
method of fitting this model by reconstructing cohort data using re-sampling. A 
simulation study reveals that the proposed method is accurate in fitting the parameters of 
the TSCE model in the case where there are no known exposures. 
Risk factors for lung cancer have been extensively researched. The main risk for 
lung cancer comes from tobacco smoke, including smoking but also to a lesser extent 
exposure to second-hand smoke. Other risk factors for lung cancer include exposure to 
radon, asbestos, and air pollution. Also, genetics plays a role as having a family history of 
lung cancer increases risk for lung cancer (NIH 2007). Findings from epidemiological 
studies on risk factors will be discussed in the background section. 
In this thesis, I use a new resampling based method to reconstruct time to event 
data from the combination of case-control data and incidence/mortality rate data. Using 
the method, I fit a TSCE model based on smoking history. Using simulation, I validate 
the model against the heavy-smokers control arm of CARET. Also, using the CISNET 
smoking history generator, the model is able to simulate US LC mortality rates. 
In 2006 as part of Li Deng's thesis and later published (Deng et al. 2009), the 
TSCE model was fit to MD Anderson case-control data on lung cancer using least 
squares estimation. Deng used the model to examine the effects of smoking and DRC on 
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lung carcinogenesis in current and never smokers exclusively. My model will differ not 
only in the method used for fitting, but on the risk factors included and the inclusion of 
former smokers. 
Background information on lung cancer mortality trends, and known risk factors 
for lung cancer follow in the remainder of this chapter. The following chapter details the 
history of carcinogenesis models as well as describes the model for this study. It also 
describes the two-stage clonal expansion (TSCE) model and introduces a new method 
allowing for the model to be fit to case-control data instead of the traditional prospective 
cohort data. This thesis also includes simulation studies used to validate the accuracy of 
the method in fitting the parameters of the TSCE model. A fitted smoking based TSCE 
model is presented along with model validations. The model is then applied to a study of 
CT screening for lung cancer to determine the effectiveness in reducing lung cancer 
mortality. Discussion and future considerations are included in the final chapter. 
1.2 Epidemiology of Lung Cancer 
There are 2 major cytological types of lung cancer: non-small cell lung cancer 
(NSCLC) and small cell lung cancer (SCLC). NSCLC makes up 87% of newly diagnosed 
lung cancers and is classified according to three different types. Squamous cell 
carcinoma makes up about 25% to 30% of all lung cancer diagnoses. This type of lung 
cancer tends to be located in the middle of the lungs near the bronchus. Adenocarcinoma 
accounts for 40% of lung cancer diagnoses and develops in the mucus producing glands 
of the lungs. It is the most common lung cancer among women and never smokers. 
Large-cell undifferentiated carcinoma tends to grow rapidly and can start in any part of 
4 
the lung. This type of lung cancer accounts for 10% to 15% of lung caner diagnoses. 
SCLC makes up 13% of lung cancers and is characterized by small cells that multiply 
quickly forming large tumors that spread throughout the body quickly (NIH 2007). 
1.3 Temporal Trends in Lung Cancer Mortality 
As shown below the age-adjusted lung cancer mortality rates for men have been 
decreasing for almost 20 years while the women's rates have just stabilized. Women's 
rates of lung cancer are expected to also decline because their prevalence of smoking has 
been decreasing. African-American and white females have similar lung cancer mortality 
while African-American males have about a 50% increased mortality when compared to 
white males (Ries et al 1991). However, other races observed including: Hispanics, 
Native Americans, Alaska Natives and Pacific Islanders, have a significantly lower lung 
cancer mortality than whites and African-Americans. Mortality is chosen so that 
comparisons can be made between SEER and the Texas Cancer Information Center, 
which as of now only provides rates for mortality. 
Surveillance Epidemiology and End Results (SEER) (National Cancer Institute) is 
a comprehensive database on cancer incidence in the United States. SEER provides data 
on cancer incidence, mortality and survival from 15 population-based cancer registries in 
the United States. SEER currently includes information on approximately 26% of the US 
population. 
The Texas Cancer Information Center (Texas Cancer Registry), formerly known 
as the Texas Cancer Data Center tracks mortality on the different types of cancer in 
Texas. From this data center, Texas lung cancer mortality for selected years by age, sex, 
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race, and geographic area can be obtained. As of now, Texas is not included in SEER. 
One major difference between the Texas Registry and SEER is that the race Hispanic is 
defined as a separate race class in the Texas Cancer Registry. This resource will also be 
providing cancer incidence information in the near future. 
As seen in the graphs on the next page, overall Texas and SEER mortality rates 
are similar in both men and women. 
Age-Adjusted Lung Cancer Mortality- Males 
160 i 
140 -
1?0 -
o 
o 
o 100 -o 
ffl 
a 80 -
2f 
¥ fiO -
o 
E 
40 -
20 -
0 
-SEER 1973-2004 all races 
-SEER Whites 
-SEER Blacks 
-SEER other 
-TX 1990-2004 all races 
-TX Whites 
-TX Blacks 
-TX Hispanics 
-TX other 
A A A A ^ A A A A A (4 (9 ^ (v> & & & fP >°P
 N<£> >$? ^ 
year 
Figure 1.1 Age-adjusted lung cancer mortality rates for males 
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Age-Adjusted Lung Cancer Mortality Rates- Females 
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Figure 1.2 Age-adjusted lung cancer mortality rates for females 
Although data is collected on Hispanics, data on Hispanic heritage is collected separately 
from race. So, Hispanics can be included in any of the race assignments, whites, blacks, 
and other. Other races in SEER include American Indians, Alaska Natives, and Pacific 
Islanders. 
1.4 Risk Factors for Lung Cancer 
The primary risk factor for lung cancer is smoking but there are other known risk 
factors including exposure to asbestos, radon, and secondhand smoke. There is also 
known to be a genetic risk effect because relatives of individuals with lung cancer have a 
higher risk of developing lung cancer themselves. 
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1.4.1 Smoking Tobacco 
Tobacco has been used for centuries all over the world. However, following the 
introduction of manufactured cigarettes with addictive properties the incidence of lung 
cancer has risen rapidly. Scientist in Nazi-era Germany carried out the first studies on the 
relationship between smoking and lung cancer (Proctor 1999). By the 1950's case-control 
trials in both the United States and Britain showed a strong association between cigarette 
smoking and lung cancer (Doll and Hill 1950, Levin et al. 1950, Wynder and Graham 
1950). The causal relationship between smoking and lung cancer was confirmed by large 
cohort studies including the British Physicians' Study, and the American cancer society's 
Cancer Prevention Study (US DHEW 1964). As lung cancer incidence is tracked over 
time it has been shown to follow cigarette consumption trends (Wingo et al. 1999). Cigar 
and pipe smoking has also been shown to be a risk factor for lung cancer, but on a much 
lower scale than cigarette smoking (Boffetta et al. 1999). The lower risk associated with 
smoking tobacco in these forms can be explained by the increased amount of 
carcinogenic additives in manufactured cigarettes (Alberg and Samet 2003) and by 
inhaling cigarettes' smoke deep into the lung as opposed to just the mouth and throat 
when smoking pipes and cigars (Alberg and Samet 2003). 
1.4.2 Secondhand Smoke 
Exposure to secondhand smoke (SHS) has been shown to be a risk factor for lung 
cancer (Brennan et al. 2004, Gorlova et al. 2006, Vineis et al. 2005, Surgeon General's 
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Report 2001 and 1986, NIH 1999, National Research Council (NRC) 1986, EPA 1992, 
I ARC 2002). 
An EPA report published in 1992 indicated that SHS was causally associated with 
increased lung cancer risk (Brown 1992) resulting in an additional 3,000 deaths from 
lung cancer per year. This was determined through a meta-analysis of 30 spousal 
exposure studies where never-smokers that lived with smokers were compared with those 
that did not. Further studies concluded that there was an increased risk of 20-25% of LC 
for never smokers that were exposed to SHS through their spouse or workplace. 
1.4.3 Environmental Exposures 
Workplace or residential exposures such as radon, asbestos, arsenic, silica, and 
chromium have also been shown to increase risk of LC (International Agency for 
Research on Cancer 1986, Alberg et al. 2005, Gottschall 2002, Neuberger and Field 
2003). Many of the workplace exposure risk factors have been shown to have a 
synergistic effect when combined with smoking, meaning that the risk for smokers is 
increased more than additively for each risk factor. 
Radon is a radioactive gas that is produced when uranium from rocks and soil 
decays. Underground mines contain high levels of radon gas. Studies of uranium miners 
(Lubin et al. 1994) and animal studies (Cross 1994) have established a causal relationship 
between radon gas and LC. Although radon is a major exposure for uranium miners, it 
has also been found to be present in people's homes. 
Asbestos is a substance made of long thin fibers used by manufacturers in the late 
19th century due to its resistance to heat, electricity and chemical damage. Inhalation of 
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asbestos fibers has been causally linked to many respiratory illnesses including LC 
(Selikoff et al. 1964). 
There is some belief that air pollution may cause lung cancer because of all the 
known carcinogens that are in the air. Taking into account the large daily human 
consumption of air, even low levels of carcinogens can be a health concern. Extrapolation 
about the known risks of lung cancer by the occupational exposures gives evidence to the 
conclusion that air pollution may be a risk factor for lung cancer (Doll and Peto 1981, 
Friberg and Cederlof 1978, Doll 1978). 
1.4.4 Pre-existing Lung Disease 
There are two main categories of lung disease. The first includes disorders that 
obstruct airflow such as chronic obstructive pulmonary disease (COPD), and in its most 
severe from, emphysema. The second group includes disorders where lung capacity is 
restricted due to inhaled fibrous substances as in black lung disease. Having obstructive 
lung disease such as COPD has been shown to increase risk for lung cancer in numerous 
studies (Littman et al. 2004, Mayne et al. 1999, Tockman 1994, Wu et al 1995). 
1.4.5 Family History of Cancer 
Although smoking is the single most important risk factor for lung cancer, genetic 
factors also play a role in lung cancer development. After accounting for smoking, 
several studies have found an increased risk in relatives of lung cancer cases compared to 
relatives of lung cancer controls (Sellers et al. 1987, Schwartz et al. 1996, Schwartz et al. 
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1999; Etzel et al. 2003, Cote et al. 2005). It has also been shown that 1st degree relatives 
(parents, siblings, and offspring) of never smokers with lung cancer have an increased 
risk of LC (Gorlova et al. 2006, Wu et al. 1996, Brownson et al. 1997). 
A recent analysis of 11 studies on never smokers concluded that there was a 1.5 
fold increase of LC for those with family history of LC (Matakidou et al. 2005). This 
result has also been shown for the relatives of smokers previously diagnosed with lung 
cancer (Etzel et al. 2003, Bromen et al. 2000, Mayne et al. 1999). 
1.4.6 Genetic Susceptibility of lung cancer, DNA repair capacity 
In a recent linkage analysis, a lung cancer susceptibility region 6q23-25 was 
identified (Bailey-Wilson et al. 2004). A more recent study found evidence of association 
of lung cancer with SNPs located in 15q region spanning CHRNA3, CHRNA5, and 
PSMA4 genes (Amos et al. 2007). Also, molecular epidemiological studies have 
documented a substantially increased risk for lung cancer associated with poor DNA 
repair capacity following exposure to mutagens (Wei et al. 2000, Shen et al. 2003). In 
these studies DNA repair capacity was evaluated by a host-cell reactivation assay that 
measures cellular ability to remove adducts from plasmids transfected into lymphocyte 
cultures in vitro, by expression of damaged reporter genes. A dose-response relationship 
has been demonstrated with increasing risk associated with poorer repair capacity (Shen 
et al. 2003). DRC is modulated by polymorphisms in genes in the nucleotide excision 
repair pathway (Qiao et al. 2002), which suggest its genetic determination. However, not 
only genetic factors but also smoking tends to modulate DRC: It is highest in current 
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smokers, followed by former and never smokers (Shen et al. 2003). This can be explained 
by the cells' need for increased repair in the presence of carcinogen/mutagen exposure. 
1.5 Attributable Risks 
Attributable risks are studied to determine the estimated percentage of lung cancer 
cases caused by certain risk factors. Below is a table of the estimated attributable risks for 
some of the risk factors mentioned previously. Data is taken from Alberg and Samet 
2003. 
Table 1.1 Attributable risk to lung cancer in the US population 
Risk Factor Attributable Risk 
Smoking 90% 
Occupation exposures 9 to 15% 
Radon 10% 
Outdoor air pollution 1 to 2% 
1.6 Gender Differences in Lung Cancer 
Lung cancer may differ in women and men with respect to several characteristics 
not necessarily caused by gender differences in smoking habits. Whether there is a gender 
difference in lung cancer susceptibility remains a controversial issue. Some case-control 
studies concluded that the risk of developing lung cancer due to smoking is higher for 
women than for men (Risch et al. 1993, Zang and Wynder 1996), whereas other case-
control as well as cohort studies show that the risks are similar (Bain et al. 2004, Prescott 
et al.l 998, Sobue et al. 2002). 
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Among never smokers, it has been shown that women are disproportionately more 
affected by lung cancer than men (Subramanian et al. 2007). Even after adjusting for the 
fact that there is a larger proportion of never smoking females than never smoking males, 
there is still a small increased risk for female never smokers as compared to male never 
smokers. Wakelee et al. (2007) in the analysis of several cohorts have shown that lung 
cancer incidence in never smoking women was higher than in never smoking men for 
most of the cohorts analyzed. 
A recent finding by IELCAP investigators Henschke and Miettinen (2006) 
showed that females, with tobacco exposure similar to that in men, had a higher risk to be 
diagnosed with lung cancer on CT screen, indicating that women are more susceptible to 
tobacco carcinogens. However, an analysis by Bain et al. (2004) comparing the Nurses 
Health Study and the Health Professionals Study showed that there were no lung cancer 
incidence differences for men and women with similar smoking histories. This study also 
noted a non-statistically significant increase in the lung cancer incidence for female 
smokers above the age of 60 compared to male smokers. 
The progression rate of the disease also shows gender differences. It was 
suggested that women have slower growing tumors than men (Hasegawa et al. 2002, 
Usuda et al. 1994,). SEER data suggest that females tend to be diagnosed with a less 
advanced stage of lung cancer compared to men. However, the age at diagnosis over all 
cell types combined is slightly earlier in women than in men. SEER data show that 
postmenopausal women (older than 50) had better lung cancer survival than men in the 
same age group while there was no difference for younger females vs. males (Moore et 
al. 2003). To what extent these differences are caused by differences in smoking patterns 
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between females and males, which are substantial (Patel et al. 2004), is not clear because 
SEER data on smoking histories is not available. A TSCE model fitted to the gender-
specific data from the MDACC case-control study, the Nurses Health Study, the Health 
Professional Study and CPS-I, all of which provide information on smoking, will help 
answer these questions related to the gender differences in lung cancer progression at its 
early stages. 
1.7 Lung Cancer in Never Smokers 
Many differences between lung cancers in smokers compared to lung cancers in 
never smokers have been shown (Sun et al. 2007). First, as noted in the previous section 
women never smokers are more often affected than men. Also, there is an increased 
incidence of the adenocarcinoma histological type of lung cancer in never smokers. 
Studies from Asia including data from Japan, Hong Kong, and Singapore show that there 
is an earlier age at diagnosis for never smokers with lung cancer than smokers with lung 
cancer (Toh et al. 2006, Shimizu et al. 1984, Koo et al. 1985). However, many studies 
from the United States and Europe show that the age at diagnosis for never smokers with 
lung cancer is the same or older than that for current smokers (Dibble et al. 2005, 
Brownson et al. 1998, Muscat and Wynder 1995, Wakelee et al. 2007, Nordquist et al. 
2006). The Wakelee study included data on 9 gender specific never smokers cohorts all 
of which showed a same or later age at onset for never smokers lung cancer as seen in the 
following table. 
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Table 1.1 Median age at LC diagnosis by smoking status (Wakelee et al. 2007) 
Cohort Never 
Smoking Status 
Former Current 
Nurses Health Study, 
female 64 68 64 
Health Professionals' 
Follow-up Study, male 67 71 68 
California Teachers' 
Study, female 67 70 67 
Multiethinic Cohort 
Study, male 72 72 69 
Multiethinic Cohort 
Study, female 72 70 67 
Swedish 
Uppsala/Orebro Lung 
Cancer Registry, male 64 71 64 
Swedish 
Uppsala/Orebro Lung 
Cancer Registry, female 67 66 63 
First National Health 
and Nutrition 
Examination Survey 
Epidemiological Follow-
up Study, male 78 72 69 
First National Health 
and Nutrition 
Examination Survey 
Epidemiological Follow-
up Study, female 71 67 62 
The lower ages at diagnosis seen in the Asia studies may be explained by more exposures 
to other risk factors including exposure to poorly ventilated fumes from cooking and the 
burning of coal. Studies have shown that cooking oil fumes, common in Asia, are a risk 
factor for lung cancer (Boffetta and Nyberg 2003). 
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1.8 Screening for Lung Cancer 
Screening for lung cancer is currently a very controversial topic. There are 3 
widely cited studies from the 1970's that all failed to show a benefit from x-ray screening 
for lung cancer (Early lung cancer detection 1984). However, advances in technology 
specifically CT, gives some hope for a screening tool for lung cancer. The 5-yr survival 
for rate for stage I lung cancer is 70% while the 5-yr survival rate for stage IV is only 5% 
(Unger 2006). If lung cancer can be diagnosed earlier when survival is better, then there 
may be hope in lowering lung cancer mortality. 
Some studies indicate a possible benefit for CT screening in Lung Cancer 
(IELCAP 2006) in terms of increased survival for stage I screen-detected lung cancers. 
However, this study is missing a control arm for comparison, and other studies dispute 
any significant mortality reduction (Bach 2007). 
1.8.1 CT Screening for LC 
The first published American study on CT screening for lung cancer was the 
Early Lung Cancer Action Program (Henschke et al. 1999, Henschke et al. 2001). 
IELCAP recently reported among participants with screened detected stage I lung cancer 
that underwent resection within 1 month of diagnosis the 10-year survival was 92% 
(IELCAP 2006) while 8 patients who declined surgery all died within the next 5 years. 
The authors argue that screening detects lung cancer at an earlier stage where curability is 
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higher leading to more lives saved. However, there is no control arm in this study with 
which to compare survival and mortality. 
Also, a measure such as survival in this type of study can be biased (Aberle 
2008). One type of bias is lead-time bias. This type of bias suggests that survival is 
increased simply because the cancer is diagnosed earlier but the diagnosis did not delay 
death from lung cancer at all. In essence, the individual discovered they were going to die 
sooner than they would have without screening, but treatment did not do anything to 
change the overall outcome. So, the time between lung cancer diagnosis and death was 
increased just because the cancer was diagnosed earlier and there was no effect on 
delaying the death. Another possible bias is length bias where screening is more likely to 
pick up slowly progressing cancers than faster growing cancers. The third bias which is 
the extreme case of length bias, is termed "overdiagnosis". The overdiagnosis argument 
is that screening mostly detects very slow-growing cancers that would not have 
progressed anyway leading to "overdiagnosis" of lung cancer in the screened group. 
Comparing the mortality in screened arm to that in a control arm is the only way to adjust 
for these possible biases. 
A recent study by Bach et al. used a previously validated model for lung cancer 
risk (Bach et al. 2004, Cronin et al. 2006) in order to simulate a control arm for 3 small 
CT screening trials. Using this method it was found that there was no reduction in 
mortality between the observed screened arm and the expected mortality from the model 
(Bach et al 2007). One major criticism of this study is that it is sensitive to the 
assumptions used in order to fit the model, and the fact that the follow-up time in the 
screening studies was too short. 
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These two studies with opposing viewpoints (IELCAP 2006, and Bach 2007) 
were published within 6 months of each other. A nice discussion comparing the 2 studies 
and their strengths and weakness was written by Black and Baron (2007). In this paper 
Black and Baron state that the best way to avoid the problems associated with these 2 
studies is using a randomized control trial (RCT) to determine if lung cancer screening is 
effective. There is an ongoing RCT of screening for lung cancer comparing CT screen 
with x-ray screen being conducted in the United States, National Lung Screening Trial 
(NLST) but there are concerns that it may not be powered to detect a difference in 
mortality because the control group is not receiving standard of care (no recommended 
screening) but is in fact being screened as well using chest x-ray. 
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Chapter 2 
Carcinogenesis Modeling 
2.1 Review of Carcinogenesis Models 
In the 1950's Armitage and Doll (1954) introduced a multi-stage model to 
describe carcinogenesis. The Armitage-Doll model described the process of 
carcinogenesis as a finite number of mutations turning a normal cell into a malignant cell. 
Normal cells undergo k distinct transformations to become malignant. This model was 
developed through the observations that for many caners, the log of incidence was linear 
in log of age. Incidence was modeled as: I(t) = ax tk~l, where t is age. This was derived 
from the following. The probability that mutation i occurs in [0,/] is ptt. Then by time t, 
k-1 
the probability that k-1, mutations occurred is (/?,/). There are (k -1)! possible 
;=1 
combinations of the mutations, only one of which is in the right order to produce the 
1 k~l 
malignant transformation. This gives the density function f ( t ) = ]~T(/?,)^ 1, 
( * - l ) ! <=i 
which leads to an incidence function of the form: I(t) = ax tk~l. 
In their 1954 paper, the model was successfully fit to English data on the 
incidence of esophageal, stomach, pancreas, and colon cancers. However, the model did 
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not seem to fit incidence data on lung, bladder, prostate, and female reproductive cancers. 
The authors suggested that these cancers did not fit because of the involvement of other 
risk factors such as smoking, and hormonal fluctuations. 
2.1.1 Two-stage Carcinogenesis Models 
It was then theorized that the poor fit could result from the fact that the Armitage-
Doll model ignores the fact that many cancers develop from the proliferation of pre-
malignant abnormal cells. In response to this Armitage and Doll (1957) introduced a 
model with two stages, the first step involving the mutation of a normal cell (NC) into an 
intermediate cell (IC), and the second step involving the further mutation of the 
intermediate cell into a malignant cell (MC). This newer model allowed for the 
proliferation of the intermediate cells by modeling it as exponential growth of the 
intermediate cells in the first stage and malignant cells escape from control in the second 
stage. 
In 1960, Kendall introduced a two-stage model in which 1st stage involved a 
subcritical birth and death process (birth rate < death rate) of the intermediate cells. The 
second stage involved a supercritical birth and death process of malignant cells. Neyman 
and Scott (1967) introduced a two-stage model where the IC's generate clones according 
to a subcritical birth and death process. 
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2.2 Two-stage clonal expansion (TSCE) Model 
With the advance of molecular biology, clonal expansion was recognized as an 
essential stage in carcinogenesis (Marks et al. 2007, Sikkink et al. 2003). Motivated by 
the idea of clonal expansion, Moolgavkar et al. (1979) established a two-stage clonal 
expansion (TSCE) model. This model is depicted as follows: 
a{t) 
lag-time 
I m 
Figure 2.1 Depiction of the TSCE model 
The TSCE model assumes that a normal cell (NC) mutates into an initiated cell (IC) 
in the first transition, according to a Poisson process with intensity v(0, where t denotes 
the age. There are X normal cells in the tissue at birth or maturity, depending on the 
tissue. Then the initiated cell duplicates or dies according to a birth-death process with 
parameters a(t) and fi{t) and forms a clone of initiated cells. Each initiated cell can also 
mutate into a malignant cell (MC) for the second transition according to a Poisson 
process with parameter ju(t). After a lag time, this malignant cell is assumed to develop 
into a cancerous tumor with probability one. The distribution of the lag-time can be 
specified and the parameters of the lag-time distribution can be fitted simultaneously with 
the parameters of the TSCE model. This model also allows for the growth of the number 
of NC's (X) through a deterministic model. 
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This modeling framework allows for evaluating the effects of different lung cancer 
risk factors on the model parameters and ultimately on cancer incidence, by making the 
model parameters dependent on the risk factors through response functions. 
2.2.1 Non-identifiability in the TSCE Model 
The TSCE model is an incidence-based model, meaning that it is set up to fit 
incidence data. One deficiency with the model is that only 4k-l of the 4k biological 
parameters v, pi, a, and /? are identifiable when fitting to data in the piecewise-constant 
parameters over k distinct time intervals. There are two widely accepted approaches to 
dealing with the non-identifiability problem. The first approach is to set the background 
mutations rates equal to each other, VO = JUQ, and assume a reasonable number of normal 
cells such as, X= 107. This approach makes use of the fact that the only the product (vju) 
appears in the survival and hazard functions. So, using this assumption will not affect 
estimates of incidence rates and risk. 
Another possible approach to the non-identifiability problem is to use a new set of 
parameters. Heidenreich et al. (1997) found that the following 4 parameters are 
identifiable when fitting the TSCE model to incidence data in the piecewise constant 
case: 
y, = v,M0 
m, Mo 
r, 
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The parameters, Y, m, y, and q have biological interpretations, yet they are less 
straightforward than the original biological based ones. Y can be interpreted as the 
initiation rate, m as the malignant transformation rate, and y as the net proliferation rate of 
the ICs. The q parameter is related to the asymptotic height of the hazard function but is 
more difficult to interpret. All of these parameters are identifiable when the model is 
fitted to incidence data. 
2.2.2 Evolution of the TSCE model 
As mentioned in the previous section, Moolgavkar et al introduced the TSCE 
model in 1979. Since then there have been many discoveries regarding this model. In the 
early 1990s Tan derived a general formula to calculate the hazard and survival functions 
of the time to first malignant cell under the TSCE model with piece-wise constant 
parameters (Tan 1991). These formulas were derived using probability generating 
functions but required a numerical approximation to solve partial differential equations. 
In 1994 the closed form solutions to the hazard and survival function of time to 
the first malignant cell were derived independently by Kopp-Schneider et al. (1994) and 
Zheng (1994) under the constant parameter setting. Then in 1996 Heidenreich showed 
that only three of the four parameters were identifiable when fitting to incidence data and 
suggested alternative identifiable parameters. 
Finally in 1997, Heidenreich was able to derive the exact hazard and survival 
functions for the TSCE model under piecewise constant parameters. This paper included 
easily programmable recursion formulas for the exact calculations and made it easier to 
use the model because it did not require numerical approximations. In this paper, 
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Heidenreich argued that in the piecewise constant setting over k subintervals of time, only 
4k-l parameters out of 4k are identifiable. This was mathematically proved in Deng's 
thesis (Deng 2006). 
2.2.3 TSCE Models Applied to Lung Cancer 
The TSCE model is widely used in risk analysis and has been used before in the 
estimation of the effects of smoking and other risk factors on transition rates and 
incidence of lung cancer. 
In 1990 Moolgavkar and Luebeck fit the TSCE model with time dependent 
parameters to data on radon induced lung tumors in rats. This model required the 
numerical approximation to calculate the survival and hazard functions. Later 
Heidenreich et al. (1999) fit the same data to the TSCE model using the exact formulas. 
This analysis also differed from the previous in that it defined two types of lung tumors in 
the radon exposed rats, incidental and fatal. 
The model has been fit to many cohorts to estimate the effects of different risk 
factors on lung carcinogenesis. In 1997 atomic bomb survivors were used to estimate the 
risk of large exposures to radiation (Heidenreich et al. 1997). Data on Colorado uranium 
miners were modeled to estimate the effects of smoking and radon exposure on lung 
cancer risk (Luebeck et al. 1999). A cohort of Chinese tin miners was used to estimate the 
effects of tobacco, arsenic, and radon on the incidence of lung cancer (Hazelton et al. 
2001). In 2006 a Canadian cohort was fit to estimate the effects of whole body radiation 
on lung carcinogenesis (Hazelton et al. 2006). More recently, the model has been applied 
to cohorts from CPS-I, CPS-II, the British Doctors Study, the Health Professionals 
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Follow-up Study, and the Nurses Health Study to estimate the effects of smoking on lung 
carcinogenesis (Hazelton et al. 2005, Meza et al. 2007). 
In this section we outline the traditional maximum likelihood approach used to fit 
the TSCE model to prospective cohort data. Then we introduce a new resampling based 
method of reconstructing cohort data from the combination of case-control data on risk 
factor dependencies and tabled incidence/mortality rate data. This method is then applied 
to a simple model. 
2.3.1 Prospective Cohort-based Likelihood 
The TSCE model is usually fit to prospective cohort data using maximum 
likelihood. The cohort likelihood is defined as the product of the individual likelihoods, 
L = Y\L j. For a fixed lag-time tiag, each Lj depends on the time of entry into the study, Sj 
2.3 Fitting the TSCE Model 
, censoring or failure time, t j , and the individual's exposure history. 
h(t j - tlag )S(tj - tlag) / S(sj - tlag) if diagnosed with cancer 
- t,m) / S(s, -1. ) otherwise 
2.3.2 Re-sampling Based Method of Reconstructing Cohort Data 
In order to fit the TSCE model to case-control data a new method was developed 
to reconstruct cohort data using the combination of case-control data and tabled 
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incidence/mortality data using re-sampling. The goal of the method is to re-sample cases 
and controls in proportions reflected in the mortality data to recreate cohort data. The 
main assumption of this method is that given all matching stratam, cases and controls 
represent a random sample from the population. Each re-sampled cohort is referred to as 
a pseudo-cohort and is created by sampling individuals. Each individual is sampled as 
follows: 
1. For each individual, the age bin (5year) in which the person 
belongs is sampled based on the number of individuals in each age 
bin of the case-control study. 
2. Based on the age bin generated above, randomly sample whether 
the individual gets cancer or not based on the estimated probability 
of an individual within the sampled age bin getting cancer within 
the 5 years spanning the age bin. 
3. Once we have an age bin, and cancer status we then sample an 
individual from the case-control dataset with the same 
characteristics and use information on their risk factor exposures. 
4. The censoring or failure time of the individual is assigned as their 
age at enrollment from the case-control dataset and the age at entry 
is assigned as 5 years prior for controls and at a randomly 
distributed age in the previous 5 years for cases. 
Ages of enrollment and exit were done this way because the cancer status was sampled 
from the probability of getting cancer over a 5-year interval. If the individual does get 
cancer during the interval the timing is sampled as uniform over the interval. 
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25,000 individuals are re-sampled from the case-control dataset for each pseudo-
cohort created. Then each pseudo-cohort is fit to the TSCE model by maximizing the 
cohort likelihood in the usual way. Two hundred pseudo-cohorts are created and fitted. 
This provides 200 joint estimates of the parameters for each simulated case-control trial. 
The overall fit is assumed to be the mean estimates over the 200 runs. 
2.3.3 Re-sampling Method Applied to a Simple Model 
To further explore this method, a simpler model was assumed. For this simpler 
model, individuals go from normal to lung cancer as a simple poisson process with 
parameter, L Under this model, we can look at the likelihood in terms of only one 
parameter. 
Under the exponential model, case-control data was simulated as outlined in the 
next section. The parameter of the exponential, A, was set as 1.5 x 10~4to approximate the 
lifetime risk of cancer as 1.5% which is comparable to the lifetime risk of lung cancer in 
never smokers. Using this new method outlined above the following negative log-
likelihood was calculated for a simulated reconstructed cohort using the simple 
exponential model. 
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Simulated Cohort, true lambda=1.5 
lambda 
Figure 2.2 Cohort likelihood applied to reconstructed pseudo-cohort data 
Using the fitting regime outlined the following results were obtained for fitting the simple 
exponential model: 
Table 2.1 Results of fitting the exponential model using the resampling method 
parameter true value mean fit LCL95% UCL 95% 
k x 104 1.5 1.507 0.978 1.943 
The accurate results for fitting the simple exponential model using the new re-sampling 
method indicated that the method has promise for fitting the TSCE model to case-control 
data and prompted further simulation studies. 
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Chapter 3 
Simulation Studies 
Simulation studies were conducted on the accuracy of fitting the TSCE model 
using the resampling based method of reconstructing time to event data from the 
combination of case-control data and incidence/mortality rate data. This was compared to 
the accuracy in fitting traditional prospective cohort time to event data. 
3.1 Simulation Methods 
Simulations studies to examine the efficacy in fitting the background rates (in the 
absence of risk factors) of the TSCE model to simulated data were carried out using the 2 
different parameterizations to both traditional cohort data and using the new re-sampling 
method on case-control data. The background rates were used because they are often the 
hardest to estimate particularly in the case-control setting. 
First, individuals were simulated using the following simulation routine suggested 
by Kaiser and Heidenreich (2004). 
1. For each individual a death of other causes time, td , distributed as 
N(80,152) was simulated. 
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2. Then the probability of not developing cancer by age td was 
calculated according to the TSCE model: pTSCE = S (td). 
3. Then a uniform(0,l) random variable, u, was drawn. 
a. If u < pTSCE then time of censoring is td and no cancer 
develops during the individual's lifetime. 
b. If u > pTSCE then cancer develops during the 
individual's lifetime and is diagnosed at age, t, computed 
by inverting the survival function, u = S(t). 
Simulating 1,000,000 individuals creates a population. The population is then truncated 
to only include individuals aged 30-84. The tabled age-specific (5 year bins) incidence 
rates are then calculated from the simulated population for use in the resampling method. 
The simulation of cohorts is done by randomly sampling 25,000 individuals from the 
simulated population. For simplicity, the age at entry to the study is assumed to be birth 
for all individuals, and the lag-time from birth of the first malignant cell to lung caner is 
assumed to be zero. 
The simulation of each case-control study is done by randomly sampling cancer 
cases from the simulated population with ages of diagnosis in the range 30-80, 
comparable to entry criteria. Then an age at enrollment is simulated as N(55,10 ) for the 
controls (all the individuals in the simulated population that did not get cancer). This age 
at enrollment is reflective of the ages of unmatched controls in the MD Anderson case-
control data. The controls are then sampled from the population with ages of enrollment 
within 5yrs of the ages at diagnoses of the cases sampled previously. Each simulated 
case-control study consists of 1,500 cases and 1,500 controls. 
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3.2 Simulated TSCE Parameters 
The following sets of parameters were used to simulate the populations based on 
the 2 methods of dealing with non-identifiability. The values chosen come from two 
studies fitting the TSCE model. The biological parameters come from a study by 
Hazelton that fit to the males of the CPS-I study and the identifiable parameters come 
from a study by Heidenreich fitting males in a large German case-control study. 
Biological parameters with constraints (Hazelton 2005): 
a0 = 22.65 
Vo = ao ~ Po - Mo = °-075 
ju0=v0= 1.4 xlO"7 
X = \07 
Identifiable parameters (Heidenreich 2002): 
^o =VoMo = 0.1 lx 10~7 
So = « o " A ) -Mo =0.134 
= ("So + Vso + 4 a 0 y " o ) / 2 
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Simulated Background Incidence 
Age 
— Biological (Hazelton 2005) — Identifiable (Heidenreich 2002) 
Figure 3.1 Simulated age-specific incidence rates 
3.3 Results for Traditional Prospective Cohort Method 
As described earlier, cohort data were simulated according to the TSCE model 
and then parameters were estimated using maximum likelihood. The following table 
shows the results of the simulation study. 
Table 3.1 Results of fitting simulated data using traditional prospective cohort method 
true Mean LCL UCL 
Type parameters value fit 95% 95% 
a 22.65 23.400 7.327 40.499 
Biological r 0.075 0.0759 0.0660 0.0857 
/^xlO7 1.4 1.3784 1.0541 1.7233 
yxlO1 0.11 0.1125 0.0603 0.1788 
Identifiable g 0.134 0.1343 0.1257 0.1443 
q x 106 1.2 1.2128 0.7255 1.8943 
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The following plots contain the actual and average predicted incidence from the 200 
simulated studies as well as predicted incidence for 20 random runs. 
Simulated incidence from fits- Biological Parameters 
age 
mean A actual Individual fit 
Figure 3.2 Predicted incidence rates- traditional cohort method with biological parameters 
Simulated incidence from fits- Identifiable Parameters 
age 
mean A actual Individual fit 
Figure 3.3 Predicted incidence rates - traditional cohort method with identifiable parameters 
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The top graph is for the biological parameters while the lower graph is for the identifiable 
parameters. Both sets of parameters can be accurately fit using the traditional cohort 
likelihood as expected. 
3.4 Results for Resampling Method 
As mentioned previously, a simulation study was conducted on the effectiveness 
of reconstructing cohort data using resampling to fit the TSCE model. This method seeks 
to use case-control data on risk factors and mortality rate data to reconstruct time-to-
event data as would be seen in a prospective cohort study. The following table shows the 
simulated fits as compared to the actual parameters. 
Table 3.2 Results of fitting simulated data using the resampling method 
Type parameters 
True 
value mean fit LCL95% UCL95% 
a 22.65 25.271 65.487 
Biological r 0.075 0.0787 0.0612 0.1032 
/ /x lO 7 1.4 1.3301 0.7028 2.0042 
^ x l O 7 0.11 0.1086 0.0189 0.2630 
Identifiable g 0.134 0.1372 0.1186 0.1600 
q x 106 1.2 1.1462 0.2888 2.7148 
The method appears to be accurate in fitting the baseline parameters of the TSCE model 
but not as precise as using traditional cohort data resulting in wider confidence intervals. 
The overall procedure was then repeated 200 times and average parameter fits were 
calculated. The results are depicted in the following graphs. 
34 
Simulated incidence from fits- Biological Parameters 
120 
•P 4> t? £ 4 
age 
•mean --^—actual 
4> 
- Individual fit 
Figure 3.4 Predicted incidence rates- resampling method with biological parameters 
Simulated incidence from fits- Identifiable Parameters 
350 
£ 
age 
-actual -Individual fit 
Figure 3.5 Predicted incidence rates- resampling method with identifiable parameters 
The mean incidence rate was calculated as the average parameter fit over the 200 
simulations. The identifiable parameters seem to produce some bias when averaging. 
Therefore, we chose the biological parameters for fitting the model to the MDA case-
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control data because they provide a better fit and are easily interpretable. 
36 
Chapter 4 
Smoking Based TSCE Model and Validation 
A smoking based TSCE model was fit using the resampling based method. A 
model based of smoking alone was chosen so that it could be used in CISNET's Smoking 
Base Case, as well as, to simulate LC mortality in the absence of screening for a single 
arm CT screening trial. The data used to fit the model, the method of reconstructing 
cohort data, and the final fitted model are presented in this chapter. Also, simulation is 
used to validate the model as a predictor of lung cancer mortality in the non-asbestos 
exposed control arm of CARET. The model is also used as part of the CISNET Smoking 
Base Case Project. 
4.1 MD Anderson Case-Control Data 
An important component to this project is to determine the effect of different risk 
factors on the process of cancer development. Datasets such as SEER contain information 
about overall lung cancer incidence and mortality but do not provide information about 
individual risk factors such as smoking. A case-control study is currently underway in the 
M.D. Anderson Cancer Center Department of Epidemiology under the direction of Dr. 
Spitz. In this study, measurements of DNA repair capacity, as well as data on other risk 
factors such as smoking are being recorded. Cases of lung cancer are matched with 
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cancer-free controls on age (within 5yrs), gender, ethnicity, and smoking status. The MD 
Anderson case-control data contains information on over 6,000 matched cases and 
controls. 
Table 4.1 Characteristics of cases (n=3433) and controls (n=3132) available from the lung cancer case-
control study (R01 CA55769, Spitz, PI) 
Characteristic Cases Controls 
Mean Age (SD) 62.3(11.1) 59.4 (10.9) 
Race/Ethnicity n (%) n (%) 
White 2744 (79.9) 2488 (79.4) 
Black 488 (14.2) 411 (13.1) 
Hispanic 173 (5.0) 210 (6.7) 
Other 28 (0.8) 23 (0.7) 
Sex 
Male 1848 (53.8) 1587 (50.7) 
Female 1585 (46.2) 1545 (49.3) 
Smoking Status 
Current 1371 (39.9) 1120 (35.8) 
Former 1453 (42.3) 1274 (40.7) 
Never 556(16.2) 702 (22.4) 
Analyses in this study will be based on a subset of whites, 992 males and 919 females, 
because of the low sample sizes of the other races. Even though cases and controls were 
matched on smoking status, the cases smoked more than the controls as seen in terms of 
average pack-years. 
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Table 4.2 Pack-year histories for 992 white males and 919 white females included in analysis 
Smoking Avg Pack 
Character ist ics Status Number Yrs 
Males Cases Current 214 58.7 
Former 259 53.1 
Never 28 0.0 
Total 501 55.3 
Contro ls Current 168 54.5 
Former 287 43.4 
Never 36 0.0 
Total 491 44.0 
Females Cases Current 211 50.1 
Former 183 41.1 
Never 58 0.0 
Total 452 40.0 
Contro ls Current 181 36.7 
Former 197 36.2 
Never 99 0.0 
Total 467 29.7 
A family history analysis was done to determine the effects of family history on 
lung cancer risk. Logistic regression analysis was performed to test the association of 
cancer family history with lung cancer risk. Three definitions of a positive family history 
were considered. The first definition was 2 or more first degree relatives diagnosed with 
any cancer (FH1). The second was at least one relative diagnosed with lung cancer (FH2) 
and finally the third was any relative with an early onset cancer (FH3), diagnosed before 
the age of 50. The following chart shows the results of this analysis. 
Table 4.3 Results o f family history analysis 
FH1 FH2 FH3 
Males Males males 
p=0.0008 p=0.0113 p=0.3051 
Females Females females 
Number p=0.0254 p=0.0005 p=0.0302 
Males Cases 501 350 (69.9) 103 (20.6) 94(18.8) 
Controls 491 292 (59.5) 70 (14.3) 79(16.1) 
Total 992 642 (64.7) 173(17.4) 173 (17.4) 
Females Cases 452 305 (67.5) 89 (19.7) 115 (25.4) 
Controls 467 281 (60.2) 52 (11.1) 90(19.3) 
Total 919 586 (63.8) 141 (15.3) 205 (22.3) 
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From this analysis seems that the second family history definition provides the most 
significant information about lung cancer risk for both males and females in the MD 
Anderson case-control study. Although, this information is not incorporated into the 
smoking based model it shows that a family history component should be added in the 
future. 
4.2 Sources of Age-specific Mortality 
The goal of this project is to use a combination of MD Anderson case-control data 
and external mortality data to fit a carcinogenesis model and estimate the effects of 
different risk factors on lung cancer development. In order to adjust for the fact that the 
MD Anderson cases and controls are matched by both age (within 5 years) and smoking 
status (current, former, and never smokers), data on age-specific mortality by smoking 
status are needed to adjust for the biases introduced by matching. There are several 
prospective cohort studies that can provide this information including the American 
Cancer Society's Cancer Prevention Study I (CPS-I), the Health Professionals Follow-up 
Study (HPFS) and the Nurses Health Study (NHS). First, the CPS-I study includes tabled 
mortality data by race and gender. An examination of these studies, as well as, the age-
specific incidence estimates by smoking status will provide clues about which dataset is 
most reflective of the MD Anderson study participants. 
4.2.1 Cancer Prevention Study 1 
The Cancer Prevention Study I (CPS-I) is a prospective cohort study conducted 
by the American Cancer Society. There were over 1 million individuals enrolled between 
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1959 and 1960. Enrollment required participants to be over age 30 and have at least one 
family member over the age of 45. Study participants completed a baseline survey at 
enrollment and follow-up questionnaires in years 1961, 1963, 1965, and 1972 allowing 
for 12 years of follow-up. The baseline questionnaire asked information about health 
status such as height, weight, demographics, personal and family history of cancer, 
occupation, diet, alcohol and tobacco use, and physical activity. Follow-up surveys 
addressed changes in smoking and vital status. The CPS-I study contains information on 
456,491 males with known death rates for 117,199, and 594,551 females with known 
death rates for 88,353 (Thun et al in Smoking and Tobacco Monograph 8). Mortality for 
5-year age groups stratified by race, gender, and smoking status for this study is available 
in Appendix C of Chapter 3 of the Smoking and Tobacco Control Monograph 8. 
4.2.2 Nurses Health Study and Health Professionals Follow-up Study 
The Nurses Health Study (NHS) is a cohort study on females that began in 1976. 
Married registered nurses between the ages of 30 and 55 were asked to enroll. The cohort 
consists of 121,700 female nurses. Every 2 years the participants respond to 
questionnaires on a wide variety of risk factors of disease including, smoking status, 
hormone use, and diet, as well as about any health conditions with which they have been 
diagnosed. Less than 10% of participants have been lost to follow-up. 
The Health Professionals' Follow-up study (HPFS) is a cohort study on males that 
began in 1986. The cohort consists of 51,529 men employed in health professions aged 
40-75. As in NHS, the participants fill out questionnaires every 2 years about diseases 
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and health-related factors such as smoking, and physical activity. Less than 7% of 
participants have been lost to follow-up. 
4.2.3 Comparisons of Mortality Datasets 
The table below describes some characteristics of datasets that provide table 
mortality/incidence rate data stratified by age, gender, ethnicity, and smoking status. 
Table 4.4 Cohort characteristics of mortality/incidence rate data 
Smoking Status 
Study Total Never Former Current 
CPS-I males 
Subjects 134,532 92,307 42,225 174,997 
Lung Cancer Cases 4,202 215 331 3,656 
10.28 
Avg. follow-up years 
CPS-I females 
Subjects 398,459 375,649 22,810 158,727 
Lung Cancer Cases 602 573 29 621 
10.82 
Avg. follow-up years 
HPFS 
Subjects 46,050 22,431 19,632 3,987 
Lung Cancer Cases 461 58 247 156 
14.93 
Avg. follow-up years 
NHS 
Subjects 104,493 51,121 24,474 28,898 
Lung Cancer Cases 1,165 130 134 901 
23.15 
Avg. follow-up years 
42 
White Males Lung Cancer Mortality 
1000 
CL 
2? 
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30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+ 
age 
Figure 4.1 Comparison of age-specific mortality rates for white males 
White Females Lung Cancer Mortality 
-CPS-I current 
CPS-I former 
CPS-I never 
-CPS-I total 
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- HPFS current 
HPFS former 
HPFS never 
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Figure 4.2 Comparison of age-specific mortality rates for white females 
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The Texas and SEER 2002 mortality rates for lung cancer are similar for both 
sexes. The SEER 2002 rate is similar to the overall male rate for 1969 through 2004 
while for females the 2002 rate is much higher. The increase in female rates is due 
mainly to the increases in smoking among women and is reflective of the large increase 
in incidence for females over that time period. 
CPS-I rates are consistently lower in females, with the rate for current smokers in 
females comparable to the overall rate for Texas and SEER in 2002. However, the rates 
for males are consistent with HPFS, TX and SEER. The overall rate in the HPFS is much 
lower than both SEER and Texas but this could be accounted for by the lower rates of 
smoking among the HPFS participants. The never and former smoking rates for both 
CPS-I and HPFS in males indicates that both studies have comparable rates. However, 
CPS-I has a higher sample size for smokers indicating that it may be better suited for 
fitting the model to the data on males. 
For females all CPS-I rates are lower than the SEER and Texas rates. The overall 
rate for CPS-I females is similar to that of the never smokers in that study. This indicates 
that the CPS-I study rates may not be reflective of current female rates of lung cancer 
mortality most likely due to the changes in females smoking that have occured. The 
overall rates in the Nurses Health Study seems to be similar to the overall SEER and 
Texas rates indicating that the NHS would be better for fitting the model to the data on 
females. 
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4.2.4 National Health Interview Survey 
The MD Anderson cases and controls are matched by gender, race, age (within 5 
years), and smoking status. CPS-I and NHS provide age-specific incidence/mortality 
rates stratified by gender, race, and smoking status and provide the needed information to 
adjust for the matching. However, we still require one more piece of information to re-
create populational data, namely the proportion of current, former, and never smokers in 
the population by race and gender. 
The National Health Interview Survey (NHIS) is a survey study run by the US 
Department of Health and Human Services. For this study, annual surveys are conducted 
in 35,000 to 40,000 households including 75,000 to 100,000 individuals. The survey asks 
participants about a range of topics including smoking, diet and nutrition, and many other 
health and wellness related topics. More information on this study can be found at 
www.cdc.gov/nchs/nhis.htm. This study provides data on the proportion of individuals of 
each smoking status (current, former, and never) in the population in the year 2000 
stratified by gender and race. 
4.3 TSCE Model based on Smoking History 
Developing a model based on smoking as the only risk exposure allows for 
comparisons to other smoking based models in the smoking base case project of the 
CISNET lung group. The MDA case-control data, as well as the LC mortality rates by 
age and smoking status from CPS-I for males and NHS for females were used to fit the 
model. A parameterization of 5 fitted parameters with a fixed lag-time is chosen to allow 
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for the inclusion of other risk variables later and minimize the effects of non-
identifiability. The biological parameters of the TSCE model are used for the ease of 
biological inferences based on the fit. Since the TSCE model is insensitive to choice of 
lag-time, i.e. the parameters shift in response to changes in lag-time assumptions, a fixed 
lag-time of 6 years between birth of first malignant cell and death from lung cancer is 
assumed and is similar to assumed lag-times in other studies (Hazelton 2005) and is in 
accordance with disease progression models (Flehinger 1987). The following are the 
response functions that relate the parameters of the TSCE model depending on smoking 
intensity, ppd, measured in packs per day. 
X = \01 
v(t) = v0X(l + u ,x tJ ppd) 
a(t) - a0(1 + a2 x ^ppd) 
y(t) = a(t)~ Pit) - = y0 (1 + a2 x 4l>Pd ) 
The resampling routine needed to be modified because the further matching of the 
MD Anderson study including smoking status, as well as, age (within 5 years), gender, 
and race. The routine was modified to include the sampling of smoking status based on 
rates obtained from the National Health Interview Survey (NHIS) for the year 2000. The 
following routine outlines the resampling method applied to the MD Anderson case-
control data, and incidence/mortality rate data from CPS-I and NHS. 
1. The smoking status (Current, Former, Never) is sampled based on 
rates for the year 2000 from the NHIS. For males: (27.56%, 
30.41%, 42.03%) and for females (22.81%, 21.65%, 55.54%) 
respectively. 
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2. For each individual, the age bin (5year) in which the person 
belongs is sampled based on the number of individuals in each age 
bin of the case-control data for the previously sampled smoking 
status. 
3. Based on the age bin and smoking status generated above, it is 
randomly sampled whether the individual gets cancer or not based 
on the estimated probability of an individual within the sampled 
age bin to get cancer within the 5 years spanning the age bin. This 
estimate is based on the tabled smoking-status-specific incidence 
data. 
4. Once the age bin, smoking status and cancer status are determined, 
an individual is sampled from the case-control dataset with the 
same characteristics and information is used concerning his/her 
risk factor exposures. 
The censoring or age at onset (operationally, the age at LC diagnosis) of the individual is 
assigned as their age at enrollment from the case-control dataset and the age at entry is 
assigned as 5 years prior for controls and at a randomly (uniformly) distributed age in the 
previous 5 years for cases. The resulting fit for a fixed lag-time of 6 years is shown in the 
following table. 
Table 4.5 Parameter fit for the TSCE model based on smoking 
Parameter ao Yo a\ ai 
Males (CPS-I) 2.99 (~10"4,12.54) 0.069(0.064,0.074) 2.17(1.88,2.50) 2.66(0.78,4.86) 0.35(0.08,0.66) 
Females (NHS) 4.60(~10"4,20.65) 0.071(0.065,0.080) 1.93(1.56,2.19) 2.30(0.36,4.56) 0.35(0.02,0.72) 
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The parameter estimates for males and females show no statistically significant 
differences. As expected the smoking related variables are statistically significantly 
positive, showing that smoking does in fact speed carcinogenesis and increase risk for 
lung cancer. The parameter estimates indicate that smoking one pack-per-day more than 
triples the mutation rates, and increases the net proliferation rate of initiated cells by 35%. 
The following graphs show predicted incidence curves for given smoking 
histories, lifetime smokers starting at age 18, former smokers starting at age 18 and 
quitting at age 40, and never smokers. The smoking intensity is assumed to be 1 pack per 
day. 
Predicted Incidence Rates 
age 
—•—Current Smoker- males —o— Former Smoker- males 
—•— Never Smoker-males —•— Current Smoker- females 
—•— Former Smoker- females —•— Never Smoker- females 
Figure 4.3 Model predicted incidence rates 
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The predicted incidence rates for former and never smokers are similar in both men and 
women. However, for life long smokers, males have a slightly higher predicted incidence. 
Since the parameters don't differ significantly by gender, the predicted incidence can not 
be shown to differ, which is in agreement with a study of the NHS and HPFS cohorts that 
showed no statistically significant difference in lung cancer risk in men and women with 
comparable smoking histories (Bain et al. 2004). However, there was a study based on a 
CT screened cohort that showed that women have a higher incidence of lung cancer and 
also higher lung cancer survival (IELCAP investigators 2006). Women are known to 
have a disproportionately higher percentage of never smokers with lung cancer when 
compared to men (Subramanian and Govindan 2007) but this may be due to exposures to 
secondary risk factors. 
4.4 Predicting LC Mortality in the CARET study 
The estimates were validated by applying the resulting model to data on smoking 
histories from the non-asbestos exposed control arm of the CARET trial for validation 
purposes. The smoking based model was used to predict cumulative LC deaths in the 
non-asbestos exposed control arm of the CARET (Carotene and Retinol Efficacy Trial) 
study for comparison against the observed LC deaths. The CARET study was a double 
blind, placebo control trial on the effect of beta-carotene and retinol in the prevention of 
lung cancer. The non-asbestos exposed group included 7965 men and 6289 women with 
at least a 20 pack-year smoking history, were aged 50-69 and were current smokers or 
had quit within the previous 6 years. The study was stopped early when it showed that 
use of the supplement provided no reduction in cancer. Prior to randomization all 
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participants were given placebos for 3 months to determine their adherence to taking the 
vitamins. For this study, data was obtained on the non-asbestos exposed placebo-control 
arm of the CARET study including data on 6877 individuals (3797 males and 3080 
females). 
Expected Lung Cancer mortality is calculated based on the individual-level data 
on smoking history, dk, and age at enrollment,. For each year of follow-up, j, the 
probability that individual, k, will die from lung cancer is calculated using the following 
formula where lk y denotes the length of time that individual k was followed up through 
year j and tk . is that individual's age at the start of follow-up year j. The probabilities are 
conditioned on the fact that participants have not died of lung cancer by age at 
enrollment, tk,. 
_S(tkJ+lkJ;dk)-S(tkJ;dk) 
Pk
'
J
 S(tky,dk) 
If an individual was not followed up during the follow-up year j, then pkj = 0 . 
Then total expected lung cancer deaths, E, in follow-up year j is Ej = ^  pkJ and the 
k 
j 
cumulative expected deaths, D, by follow-up year j is then Dj = ^  En . 
n = l 
The calculated probabilities pk J , determined the simulation of lung cancer mortality in 
the CARET study based on the model. The simulation was conducted using the 
probability of never dying of lung cancer during the study for each individual, 
1 - ^ pk j , and the individual follow-up year probabilities of lung cancer death, pk J . 
j 
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In a single simulated study, whether or not lung cancer death occurs is simulated 
for each individual. If an individual does die from lung cancer then the year of follow-up 
at which the individual dies is simulated according to the probabilities. The cumulative 
number of lung cancer deaths per follow-up year is calculated for each simulated study. 
The simulation is repeated 5,000 times to compare expected lung cancer mortality and 
produce confidence intervals. 
The mean predicted cumulative LC mortality as well as confidence limits are 
depicted in the following figures. The model produces accurate predictions for overall 
lung cancer mortality in the CARET study. There were 364 LC deaths in the course of 
the CARET study and the model predicted 366.8 (CI 331-402). The model was also able 
to predict LC deaths for males and females within confidence limits as shown in the 
following chart. 
Table 4.6 CARET study predicted and observed LC deaths 
Overall Males Females 
Observed 
Predicted 
364 
366.8(331,402) 
225 
236.8(208,266) 
139 
130.0(109,152) 
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LC Mortality by year 
— — Upper Confidence Limit 
— - • — Lower Confidence Limit 
"Expected Deaths 
"Observed deaths 
Figure 4.4 Yearly predicted and observed LC deaths- CARET 
Overall Cumulative LC Mortality 
year of follow-up 
— • • — Upper Confidence Limit • Expected Deaths — - • — Lower Confidence Limit Observed deaths 
Figure 4.5 Cumulative predicted and observed LC deaths- CARET 
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Figure 4.6 Yearly predicted and observed LC deaths- CARET males 
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Figure 4.7 Cumulative predicted and observed LC deaths- CARET males 
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Figure 4.9 Cumulative predicted and observed LC deahts- CARET females 
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The yearly number of LC deaths predicted and observed suggest that there may be 
some healthy volunteer bias in the participants of CARET. Observed LC mortality was 
lower than predicted for the first year in females and in years 1-3. However, at about year 
10 of follow-up we start to see the opposite trend. After about year 10, there are some 
years with more observed LC mortality than predicted. This effect could be seen when 
healthier participants are lost to follow-up more often than unhealthy participants. Less 
healthy who know that they are at high risk may be more inclined to remain in the study 
than participants who feel healthy. Those who feel healthy later may not see the benefit 
of remaining in the study and thus be more likely to drop out. These effects seem to 
balance each other by the completion of follow-up. 
Removing these effects to determine the models ability to predict LC deaths is 
important. In order to fully remove healthy volunteer effect the first 3 years are removed. 
The model is used to predict LC mortality in years 4-10 for comparison against the 
observed. This time interval is used because it removes any possible healthy volunteer 
effect as well as any underestimation in the later years. It is also the same interval that 
will be used in the CT screening simulation. The following graphs show the observed and 
predicted LC deaths in years 4-10. The model seems to do very well in predicting lung 
cancer mortality in these years. 
Table 4.7 CARET predicted and observed LC deaths (years 4-10) 
Overall Males Females 
Observed 
Predicted 
212 
207.0(180,235) 
142 
133.6(112,156) 
70 
73.4(57,91) 
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Cumulative LC Deaths Adjusted for Healthy Cohort Bias (years 4-10) 
year of follow-up 
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Figure 4.10 Predicted and observed cumulative LC deaths- CARET (years 4-10) 
Cumulative LC Mortality adjusted- Males (years 4-10) 
year of follow-up 
— • • — Upper Confidence Limit • Expected Deaths — - • — Lower Confidence Limit * Observed 
Figure 4.11 Predicted and observed cumulative LC deaths- CARET males (years 4-10) 
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Cumulative LC mortality Adjusted- Females 
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Figure 4.12 Predicted and observed cumulative LC deaths- CARET females (years 4-10) 
4.5 Simulating US LC mortality 
The smoking history generator provided by CISNET and the model based on 
smoking, are used to simulate LC mortality in the US population for comparison against 
the observed. Given year of birth, gender and race, the smoking history generator 
provides a smoking history and age of death td from causes other than lung cancer. Using 
each individual's unique smoking history and death of other cause times, LC mortality is 
simulated according to the model based on the parameter estimates obtained by the 
resampling method, using the following simulation routine suggested by Kaiser and 
Heidenreich (2004). 
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1. Then the probability of not developing cancer by the age at death 
from any other cause td was calculated according to the TSCE 
model: pTSCE = S{td). 
2. Then a uniform(0,l) random variable, u, was drawn. 
a. If u < pTSCE then time of censoring is td and no cancer 
develops during the individual's lifetime. 
b. If u > pTSCE then cancer develops during the individual's lifetime 
and is diagnosed at age, t, computed by inverting the survival 
function, u = S(t). 
50,000 individuals were simulated per birth cohort 1891-1970. After the birth 
cohorts are combined the year-by-year age distributions are adjusted using re-weighting 
to match the observed US population. LC mortality for males and females were simulated 
separately. The following graphs show the observed and simulated LC mortality for years 
1985-2000. 
Simulated US Mortality Rate (ages 30-84)- Males 
year 
> Simulated Observed 
Figure 4.13 Simulated and observed US LC mortality rates- males 
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Simulated US Mortality Rate (ages 30-84)- Females 
year 
• Simulated Observed 
Figure 4.14 Simulated and observed US LC mortality rates- females 
The results from this simulation show that the model can reasonably re-create US LC 
mortality. Simulation of LC mortality in the US population shows an acceptable 
prediction of US LC mortality in the period 1985-2000. However, if the mortality is 
simulated for years 1975-1985 we find that the model predicts higher than observed LC 
mortality. This could be reflective of the changes in cigarettes and smoking behaviors 
that occurred in the period 1950 through the mid 1980s, while the model was fit to more 
contemporary data. For women, the higher predictions persist through the year 1992 after 
which the predictions are accurate. 
Starting in the 1950s changes were made to cigarettes and tobacco that included 
the introduction of filters, changes in the method of curing tobacco, and marketing of low 
tar cigarettes with reduced nicotine levels. Reduced tar and nicotine cigarettes sought to 
lower the carcinogen exposure produced by cigarette smoking. While the changes did 
reduce levels of tar and some carcinogens other carcinogens were increased (Hoffman 
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1997). Also, there were observed smoking behavior changes in smokers of lower yield 
cigarettes including smoking more cigarettes per day, taking more puffs from each 
cigarette, and inhaling more deeply (Thun 2001) referred to as compensatory smoking. 
Compensatory smoking is driven by the need to maintain nicotine levels to satisfy the 
nicotine addiction. By smoking more and inhaling further into the lungs, nicotine levels 
are increased and exposures to the carcinogens in cigarettes are higher. In the mid 1960s 
a new method of curing tobacco was employed that lead to a marked increase in tobacco-
specific N-Nitrosamines. These changes in cigarettes that started in 1950 and continued 
through the mid 1980s increased the carcinogenicity of modern day cigarettes. Thus, one 
of the limitations of our model is that it does not capture the effect of changes in 
cigarettes and smoking behaviors over time. 
4.6 CISNET Smoking Base Case Project 
The CISNET lung group's smoking base case projects uses simulation to estimate 
the number of LC deaths that were averted by tobacco control policies that were initiated 
after the surgeon general's report of 1964 warning on the dangers of tobacco use. The 
project also simulates the deaths that would have been averted if smoking had been 
banned. 
The smoking history generator can be used to simulate population smoking trends 
based on 3 different scenarios. The first is based on the NHIS, referred to as the Actual 
scenario, and re-creates observed trends in smoking and mortality. The second is based 
on what would the expected smoking would be if there were no public health information 
about the dangers of smoking. It attempts to simulate smoking histories as if there were 
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no known information about the dangers of smoking and individuals continued smoking 
along the patterns observed before the 1964 surgeon general's report (US Department of 
Health, Education, and Welfare 1964). The last scenario is based on the premise that 
smoking is banned in 1965 after the surgeon general's report came out. For this scenario 
all individuals quit smoking in 1965 and there is no smoking from that point on. The goal 
of having the 3 scenarios is to quantify the effect of the tobacco control programs that 
were initiated after the surgeon general's report as compared to what would have 
happened if individuals were forced to quit. 
The following graphs show the simulated LC mortality under these 3 scenarios 
based on the smoking history generator. 
Simulated US Mortality Rate (ages 30-84)- Males 
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Simulated US Mortality Rates (ages 30-84)- Females 
year 
—•—Actual No Tobacco Control - • -Comp le te Tobacco Control Observed 
F i g u r e 4 . 1 6 C I S N E T S m o k i n g B a s e C a s e S i m u l a t i o n - f e m a l e s 
The difference between the No Tobacco Control and Complete Tobacco Control 
lines provides a measure of the potential number of LC deaths that could have been 
avoided if all smokers were forced to quit. The difference between the No Tobacco 
Control and simulated Actual LC deaths provides a measure of the realized reduction in 
LC deaths accomplished through tobacco control policy. As seen from the graph below, 
the tobacco control policies only met 40% of the total potential lung cancer death 
reduction in the years 1985-2000. 
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Proportion of LC Deaths Averted 
year 
Males -3K- Females Total 
Figure 4.17 Proportion of LC deaths averted through tobacco control policies 
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Chapter 5 
Implications for Screening 
5.1 Single-arm CT Screening Trial for LC 
The model is used to predict LC mortality in the absence of screening to use as a 
surrogate control arm for comparison against observed LC mortality in a single-arm trial 
on CT screening. The main criticism of the ongoing ELCAP CT screening study is that it 
lacks a control arm. The model is used to simulate the expected LC mortality in the 
absence of the CT screening intervention. Using data on gender, age, and detailed 
smoking history from participants in the ELCAP study, LC mortality is simulated for the 
individuals as done in the CARET study analysis. 
5.2 NY LC Screening Study 
The New York study uses CT scans as a screening tool for Lung Cancer. Study 
participants are aged 55 or older, have at least a 10 pack-year smoking history, and have 
no symptoms of LC at time of enrollment. Detailed smoking histories including age at 
initiation, age at cessation, and number of cigarettes per day smoked, were obtained from 
questionnaires at the time of enrollment. The final data set includes 7994 individuals. 
6 4 
JZL 
4 5 6 7 
follow- up year 
10 
Figure 5.1 Person-years in the NY cohort per year of follow-up 
5.3 Simulating Mortality in the Absence of Screening 
The model used predicts the risk of an individual dying from lung cancer in a 
given time interval based on individual's unique smoking history and age. The 
probability that an individual will not die of lung cancer by age t, is defined as the 
survival probability and the function as S(t). In this model S(t) depends on the individuals 
smoking history with age at initiation of smoking, i, age at cessation of smoking, c, and 
number of cigarettes smoked per day, s, and will be referred to as S(t;i,c,s). 
Expected lung cancer mortality for the study is calculated based on the individual-
level data on smoking histories and ages at enrollment provided for the NYC cohort. For 
each year of follow-up, j, the probability that individual, k, will die from lung cancer is 
calculated using the following formula where l k j denotes the length of time that 
individual k was followed up through year j and tk ] is that individual's age at the start of 
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follow-up year j. The probabilities are conditioned on the fact that participants have not 
died of lung cancer by age at enrollment, tk x. 
p _ S(?kj + hj'->h>ck>sk)~'•>h>ck->sk) 
S(tk,\>h>Ck>Sk) 
For individuals not followed up during the follow-up year j, pkj = 0 . 
Then total expected lung cancer deaths, E, in follow-up year j is Ej = ^  pk, and the 
k 
j 
cumulative expected deaths, D, by follow-up year j is then Dj - ^ En . 
n=1 
The calculated probabilities pk j, allowed for the simulation of expected lung cancer 
mortality in the NYC cohort based on the model. The simulation was conducted using the 
10 
probability of &-th individual not dying of lung cancer during the study, pk j , and 
j=i 
the individual's follow-up year probabilities of lung cancer death, pk . ,j = 1,..., 10, over 
the 10 years of total follow-up time. 
Using the probabilities defined above, lung cancer mortality is simulated for each 
individual. If the simulated individual does die from lung cancer then the year of follow-
up at which the individual dies is simulated. The cumulative number of lung cancer 
deaths per follow-up year is then calculated for each simulated study. The simulation is 
repeated 5,000 times to compare expected lung cancer mortality and produce confidence 
intervals. The confidence intervals are estimated using the 2.5% and 97.5% of the 5,000 
simulated studies. 
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5.4 Results of Screening Simulation 
The following figure provides the yearly number of expected and observed deaths 
from lung cancer in the NYC cohort together with the 95% confidence interval. The 
yearly predicted and observed LC deaths are also provided in the following table to show 
the magnitude of any healthy volunteer bias. It appears that the healthy volunteer effects 
through year 3, decreasing in magnitude from year 1 to year 3. For the main analysis the 
first 3 years of follow-up are removed to conservatively adjust for any possible healthy 
volunteer effect. 
Table 5.1 Observed and predicted LC deaths in years 1-4 in the NYC cohort 
Year of follow-up Observed Predicted 95% CI 
1 6 36.3 (25,48) 
2 13 36.7 (25,49) 
3 16 24.3 (15,35) 
4 12 14.5 (7,23) 
60 
50 
40 
« 
1 30 
(J 
20 
10 
0 
Figure 5.2 Yearly simulated and observed LC deaths in the NYC CT screening cohort 
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The following graphs show the observed and predicted cumulative LC deaths starting in 
year 4 and ending at the end of follow-up (year 10). 
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Figure 5.3 Predicted and observed cumulative LC deaths in the NYC cohort (years 4-10) 
The expected number of LC deaths for years 4-10 (first 3 years are excluded to adjust for 
healthy volunteer bias) is 45.1 and the 95% confidence interval ranges from a lower 
bound of 33 to an upper bound of 58. The observed number of LC deaths for follow-up 
years 3-10 in the screened cohort was 29. 
Another approach to determining the mortality reduction is to calculate the SMR. 
The SMR was significant for years 4-10 when the deaths of participants who dropped out 
of screening were included, 29/45.1 = 0.64, showing a mortality reduction of 36% (95% 
CI: 0.12, 0.50, P< 0.001). If the first 2 years of follow-up are removed, there is still a 
statistically significant estimated mortality reduction of 35% (95% CI: 0.17, 0.48, 
Cumulative Observed and Predicted LC Deaths- years 4-10 
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p<0.001), which is very close to the estimated mortality reduction if the first 3 years are 
excluded, indicating that healthy volunteer effect is fully removed by year 3. 
For the NYC cohort, the model predicts 45.1 LC deaths over the years 4 through 
10 of follow-up after adjusting for healthy volunteer bias in the first 3 years, compared to 
the 29 observed deaths in those years. Even conservatively dealing with healthy volunteer 
effect it appears that CT screening for lung cancer does provide a mortality benefit. 
5.5 CT Screening Controversy 
There was recently a similar analysis conducted by Bach et al (2007) on 3 
different CT screening cohorts including Instituto Tumori, the Mayo Clinic, and the 
Moffit Center which showed contradictory results to what we found in this study, 
showing no mortality benefit to CT screening for lung cancer. However, the confidence 
limits showed there could be as much as a 30% reduction in LC mortality. Some of the 
reasons for discrepancies between this study and our study could include that this 
previous study contained mortality data on only 3,210 individuals who had a median 
follow-up time of 3.7 years as compared to this analysis containing data on 7,995 
individuals with a slightly longer median follow-up time of 4.4 years. The Bach study 
also included more outcomes such as LC diagnosis and surgical resections, while this 
study focuses on LC mortality alone. The studies also differ in the modeling used to 
estimate risk of lung cancer death. 
The efficacy of CT scanning as a screening tool for lung cancer remains a 
controversial topic. As more data comes in, it should become apparent whether it can be 
reliably used to lower LC mortality. If it is proven effective then more analysis will be 
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needed to determine which individuals should be screened, how often they should be 
screened, and how should the nodules found be managed. The results from the 
randomized National Lung Screening Trial are anticipated but may not fully answer 
questions about efficacy because instead of having standard care (no recommended 
screening) the control group is being screened with x-ray, which will bias results towards 
underestimating any observed mortality benefit. 
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Chapter 6 
Discussion and Future Directions 
6.1 Summary 
In this thesis, a new method of reconstructing time to event data from the 
combination of case-control data on risk factors and tabled age-specific 
incidence/mortality rate data. This method is based on the assumption that given the 
matching stratum and cancer status, cases and controls are randomly sampled from the 
population. This method is applied to fit a two-stage clonal expansion model for lung 
carcinogenesis. Simulation studies showed that the method resulted in reasonable fits for 
this model. 
A smoking based TSCE model was fit to MD Anderson case-control data on 
smoking histories and tabled age-specific mortality rate data stratified by smoking status 
from CPS-I for males, and NHS for females. The model was fit separately for males and 
females, and the resulting parameter estimates do not statistically differ by gender. 
The model was then validated against the control group of the non-asbestos 
exposed, also known as the heavy smoker cohort of CARET. The model predicted 366.6 
LC deaths over the course of the study compared to the observed 364 resulting in an 
accurate fit. The model was able to reasonably reproduce US mortality rate trends for the 
71 
years 1985-2000 using simulation. The model was also applied to the CISNET Lung 
Group's smoking base case project. 
The model was then used to simulate LC mortality in the absence of screening, 
for use as a comparison control for a single arm trial of CT screening for lung cancer. The 
results of this effort show a 36% reduction in mortality resulting from CT screening 
intervention. 
6.2 Future Considerations 
The model can be further expanded in a number of ways. Most basically, by 
including other known risk factors for LC including family history, presence of lung 
disease such as COPD, exposures to dusts and asbestos, and genetic factors. Also, within 
the TSCE model framework the lag-time from appearance of first malignant cell to lung 
cancer diagnosis/death is assumed and the model is fit. The model itself is insensitive to 
choice of lag-times as the fitted parameters will adjust based on the assumptions. A 
TSCE model fit based on no lag-time will produce similar incidence and risk predictions 
to a TSCE model fit with different lag-time assumptions fit to the same data. In this 
study the lag-time is assumed to be a fixed length of 6 years. This is a reasonable 
assumption when compared to other studies. However, the lag-time itself could be 
modeled independently based on what is known about tumor growth and progression 
rates. Modeling the lag-time separately could also provide a framework for predicting the 
tumor size, growth rate, and histological sub-type and thus provide a more encompassing 
modeling framework. 
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Healthy volunteer bias is a well documented effect (Austin et al. 1981, Benfante 
et al. 1989, Bisgard et al. 1994, Lindsted et al. 1996, Chou et al. 1997, Etter et al. 1997, 
Froom et al. 1999, and Hara et al. 2002) in cohort studies enrolling volunteers. 
Volunteers for the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial 
(PLCO) tend to be more physically active, have higher education, and are less likely to be 
overweight than the general population (Pinksy et al. 2007). Also, a study involved in 
recruiting smokers still showed significant healthy volunteer effect (Thomson et al. 
2005). The recruited smokers had on average 15.45 hours of physical activity compared 
to the national average of less than 1 hour per week. Volunteer of this study also were 
less likely to be overweight, drank less alcohol, and had lower rates of hypertension and 
diabetes than the US national average. Every cohort is different with regards to 
recruitment, but studies involving volunteers are likely to suffer from the healthy 
volunteer effect. Although, the effect is well documented there is no current method 
designed for adjusting or removing the effect in analyses. Development of a method that 
could adjust for the healthy volunteer effect, perhaps by removing proportions of 
predicted deaths decreasing in magnitude over the first few years for a study, would help 
improve the predictions of models as well as estimate the effectiveness. 
Primary tumors can be located in different parts of the lung. Detection of more 
than one lesion is relatively common. The number and localization of the tumors is an 
important clinicopathological feature; depending on the location, a tumor of the same size 
can produce very different symptoms and outcomes. Factors affecting the spatial 
distribution of lung lesions are poorly understood. A study of these factors can shed light 
on lung cancer risk and outcomes. Using information on risk factors and tumor sizes and 
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locations, it is possible to model the spatial distribution and sizes of the tumors. It is also 
possible to further study how tumor characteristics (location, size, and number of 
lesions), influence lung cancer symptoms and prognosis. A complication of this analysis 
is that the presence of multiple tumors currently affects the stage classification and 
recommended treatment which in turn affects outcomes. Having knowledge about where 
a tumor is likely to develop and how fast it is likely to grow, based on a patient's risk 
factor history would be valuable in developing LC screening programs. 
In 1953, Slaughter et al introduced field cancerization as a theory about the spread 
of pre-malignant "fields" which give rise to tumors in oral cancers. Using data on lung 
cancer patients including data on epidemiological risk factors as well as tumor sizes and 
locations it is possible study the evidence for field cancerization in the lung by studying 
the locations of synchronous primary lung cancers. The field cancerization process has 
been in more accessible cancer cites (Braakhuis et al. 2003, 2004) including oral cancer 
(Copper et al. 1993). Genetic studies of the lung are split on whether the field exists in 
lung cancer (Franklin et al. 1997, Sozzi et al. 1995). Evidence of field cancerization may 
explain the presence of multiple lesions, and may also provide insight on the mechanism 
of recurrence for lung tumors. 
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